



MEDICAL TIPS

K-MET TABLETS

Issue VIII, No. 30, 2022

Metformin is associated with favorable outcomes in patients with COVID-19 and type 2 diabetes mellitus

Ma Z et al. Scientific Reports 2022; 12(5553): 1-7.

- Several risk factors are associated in developing severe disease with COVID-19 one of which is pre-existing type 2 diabetes.
- Metformin is known to have host directed anti-viral and anti-inflammatory properties.
- 1356 hospitalized patients with COVID-19 and type 2 diabetes were analyzed for primary outcomes like in-hospital mortality and length of hospital stay.
- It was observed that metformin therapy prior to admission was associated with a significantly less in-hospital mortality, hospice care enrolment and length of hospital stay compared to the on-metformin group.

These results provide supporting evidence that metformin may confer increased survival in patients with COVID-19 and type 2 diabetes mellitus treated with metformin prior to hospitalization.

